Investigational Therapeutics That Restore Brain Synapses
Spinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
A New Approach to the Brain’s Lost Connections
Spinogenix has designed small molecules to help restore the brain connections (synapses) in neurodegenerative, neuropsychiatric and neurodevelopmental conditions including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, schizophrenia, Fragile X Syndrome (FXS) and many others.
Latest Press Releases
Spinogenix Receives U.S. FDA Fast Track Designation for Tazbentetol for the Treatment of ALS
May 5, 2026
Designation Enables an Enhanced Development Path for Tazbentetol and Underscores the Unmet Need for New Treatments In ALS Milestone Follows Recent Announcement of Phase 2a Results Showing Preliminary Evidence that...
Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models
May 3, 2026
New Preclinical Data Show Tazbentetol Reduces Retinal Cell Loss and Preserves Visual Function in Glaucoma and Diabetic Retinopathy Models LOS ANGELES, May 3, 2026 — Spinogenix, Inc., a clinical-stage biopharmaceutical...
Spinogenix Announces CLARITY: a Phase 2b/3 trial of SPG601 for the Treatment of Fragile X Syndrome
April 23, 2026
LOS ANGELES, April 23, 2026 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, is initiating CLARITY, a Phase...
In the News
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
December 9, 2025
Topline data from a completed phase 2a trial (NCT05882695) highlighted the therapeutic benefits of SPG302, a synaptic regenerative drug, to treat patients with amyotrophic lateral sclerosis (ALS). All told, treatment...
From the Blog
Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory
December 1, 2025
Authored by Stella Sarraf, PhD CEO, Founder In September, we recognized World Alzheimer’s Month and championed the much-needed attention and awareness to one of the greatest health crises of our...